{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=68", "query": { "condition": "Relapsed, Refractory Malignant Neoplasms", "page": 68 }, "page_size": 10 }, "pagination": { "page": 68, "page_size": 10, "total_count": 3448, "total_pages": 345, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=69&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=67&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T05:14:01.546Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01492881", "title": "Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-04", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2012-05-11", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492881" }, { "nct_id": "NCT02143414", "title": "Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Recurrent Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methotrexate Sodium", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 53, "start_date": "2015-06-30", "completion_date": "2027-06-06", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 195, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 139 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143414" }, { "nct_id": "NCT05027867", "title": "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer", "Small Cell Lung Carcinoma", "Small Cell Lung Cancer Extensive Stage", "Small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "KRT-232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-12-06", "completion_date": "2022-08-26", "has_results": false, "last_update_posted_date": "2023-08-16", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 9, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027867" }, { "nct_id": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Non Hodgkin Lymphoma", "Sarcoma", "Chondrosarcoma", "Small Lymphocytic Lymphoma", "Chronic Lymphocytic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Aplitabart (IGM-8444)", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab (and approved biosimilars)", "type": "DRUG" }, { "name": "Birinapant", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGM Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2020-09-23", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553692" }, { "nct_id": "NCT00860171", "title": "Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Iodine I 131 Monoclonal Antibody BC8", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2009-02", "completion_date": "2020-03-21", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860171" }, { "nct_id": "NCT03876028", "title": "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-06-11", "completion_date": "2021-11-01", "has_results": false, "last_update_posted_date": "2023-01-31", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 2, "location_summary": "Tampa, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03876028" }, { "nct_id": "NCT01059071", "title": "Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "DFMO", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2010-02", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 7, "location_summary": "Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059071" }, { "nct_id": "NCT01396499", "title": "Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "BKM120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2012-07", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-11-01", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396499" }, { "nct_id": "NCT02142049", "title": "Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma Relapsed", "Diffuse Large B Cell Lymphoma Refractory" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "DA-EPOCH-R", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-05", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-02-05", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142049" }, { "nct_id": "NCT01300026", "title": "AMG 319 Lymphoid Malignancy FIH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Chronic Lymphocytic Leukemia", "Diffuse Large Cell Lymphoma", "Hematologic Malignancies", "Hematology", "Leukemia", "Low Grade Lymphoma", "Lymphoma", "Mantle Cell Lymphoma", "Non-Hodgkin's Lymphoma", "Oncology", "Oncology Patients", "T Cell Lymphoma", "Tumors" ], "interventions": [ { "name": "AMG 319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2011-04", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-02-09", "last_synced_at": "2026-10-18T05:14:01.546Z", "location_count": 3, "location_summary": "Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300026" } ] }